21 CFR 314.200 - Notice of opportunity for hearing; notice of participation and request for hearing; grant or denial of hearing
| Cite as | 21 CFR 314.200 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
31 practice notes
-
Food for human consumption: Food labeling Dietary supplements; effect on structure or function of body; types of statements, definition,
...a decision making standard, and the development of an record for judicial review (see section 505(c)(1), (d), and (h) of the act and; 21 CFR 314.200.) Moreover, as far as FDA is aware, the constitutionality of the new drug approval process has never been challenged on First Amendment ground......
-
Bartlett v. Mutual Pharmaceutical Co., Inc., Civil No. 08-cv-358-JL.
...on a proposal to withdraw approval of the application or the [ANDA] under [21 U.S.C. § 355(e)] and under the procedure set forth in [21 C.F.R. § 314.200], if the agency . . . (10) That the labeling for the drug product that is the subject of the [ANDA] is no longer consistent with that for ......
-
U.S. v. Undetermined Quantities of Art. of Drug, No. Civ. A. AW-00-1687.
...ordinarily be based upon published studies which may be corroborated by unpublished studies and other data and information." 21 C.F.R. § 314.200. "Substantial evidence does not consist of the expressed opinions of experts hired to testify on behalf of one party or the other. Inste......
-
Edison Pharmaceutical Co., Inc. v. Food and Drug Administration, Dept. of Health, Ed., and Welfare, No. 77-1636
...Pharmaceutical Co. v. FDA, 168 U.S.App.D.C. 273, 513 F.2d at 1067; 38 Fed.Reg. 17027 (1973). Edison then requested a hearing. 11 See 21 C.F.R. § 314.200(a)(2) (1978). The Commissioner concluded, Inter alia, that Edison had failed to set forth facts demonstrating the existence of a genuine a......
Request a trial to view additional results
9 cases
-
Bartlett v. Mutual Pharmaceutical Co., Inc., Civil No. 08-cv-358-JL.
...on a proposal to withdraw approval of the application or the [ANDA] under [21 U.S.C. § 355(e)] and under the procedure set forth in [21 C.F.R. § 314.200], if the agency . . . (10) That the labeling for the drug product that is the subject of the [ANDA] is no longer consistent with that for ......
-
U.S. v. Undetermined Quantities of Art. of Drug, No. Civ. A. AW-00-1687.
...ordinarily be based upon published studies which may be corroborated by unpublished studies and other data and information." 21 C.F.R. § 314.200. "Substantial evidence does not consist of the expressed opinions of experts hired to testify on behalf of one party or the other. Inste......
-
Edison Pharmaceutical Co., Inc. v. Food and Drug Administration, Dept. of Health, Ed., and Welfare, No. 77-1636
...Pharmaceutical Co. v. FDA, 168 U.S.App.D.C. 273, 513 F.2d at 1067; 38 Fed.Reg. 17027 (1973). Edison then requested a hearing. 11 See 21 C.F.R. § 314.200(a)(2) (1978). The Commissioner concluded, Inter alia, that Edison had failed to set forth facts demonstrating the existence of a genuine a......
-
Breitmeyer v. Califano, Civ. A. No. 7-72854.
...a more felicitous procedure for plaintiffs' purposes, in subpart C of part 314 of Title 21 of the Code of Federal Regulations. Under 21 CFR § 314.200(d) any interested person may request a hearing. The hearing, once granted, would extend to all issues relating to Essiac's status as a new dr......
Request a trial to view additional results
1 firm's commentaries
-
FDA Guidance Regarding Structure-Function Claims for Dietary Supplements
...a decision making standard, and the development of an record for judicial review (see section 505(c)(1), (d), and (h) of the act and; 21 CFR 314.200.) Moreover, as far as FDA is aware, the constitutionality of the new drug approval process has never been challenged on First Amendment ground......